News / Taiwan / economic_daily
TaiMed Biologics Eyes Profitability Milestone in 2025 Driven by Dual Growth Engines
Health Technology · Biotechnology · economic_daily · 2026-11-01
TaiMed Biologics expects a breakout year in 2025 as its CDMO services and biosimilar drug pipeline, led by the EG1206A breast cancer treatment, reach key regulatory milestones.
What Happened
Dual Growth Engines: TaiMed Biologics is leveraging its CDMO services and biosimilar drug development as primary growth drivers, resulting in significant revenue expansion this year. The company is strategically positioning itself to capture higher value in the global biopharmaceutical market.
Profitability Milestone: Chairman Liu Li-cheng has identified 2025 as a pivotal year for the company's financial performance. The firm is transitioning from a development-heavy phase toward sustainable profitability as its pipeline matures.
Regulatory Progress: The company's lead breast cancer drug candidate, EG1206A, is on track to secure regulatory approvals in both the EU and the US by the end of next year. This achievement is expected to be a major catalyst for the company's financial growth.
Future Outlook: With the anticipated drug approvals and expanded CDMO capacity, TaiMed Biologics is poised for a significant operational takeoff. Investors remain focused on how these milestones will translate into long-term revenue stability and market competitiveness.